Alzamend Neuro CEO, Stephan Jackman Says Moving Into 2024 'We Will See Topline Results From Our Vaccine Which Is Our Combined Phase I & Phase II'
Portfolio Pulse from Benzinga Newsdesk
Alzamend Neuro's CEO, Stephan Jackman, has projected that the company will see topline results from its combined Phase I & Phase II vaccine by 2024.
June 28, 2023 | 3:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alzamend Neuro's vaccine progress could potentially impact its stock positively in the short term.
The announcement of progress in a biotech company's product development, especially one that is in the clinical trial phase, often leads to increased investor confidence and can positively impact the stock price in the short term.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100